Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
RESEARCH TOOLSreports
Holding BMRN?
Track your performance easily
BMRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$63.22 - $99.56
Previous Close$63.42
Volume1.69M
Average Volume (3M)1.78M
Market Cap
$12.09B
Enterprise Value$11.75B
Total Cash (Recent Filing)$930.44M
Total Debt (Recent Filing)$594.63M
Price to Earnings (P/E)38.2
Beta0.65
Next Earnings
Feb 20, 2025EPS Estimate
$0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.66
Shares Outstanding190,583,016
10 Day Avg. Volume1,461,467
30 Day Avg. Volume1,781,072
Standard Deviation0.09
R-Squared0.03
Alpha-0.00097
Financial Highlights & Ratios
Price to Book (P/B)2.23
Price to Sales (P/S)4.54
Price to Cash Flow (P/CF)14.10
P/FCF Ratio15.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.27
Enterprise Value/Gross Profit6.17
Enterprise Value/Ebitda23.30
Forecast
1Y Price Target
$98.52Price Target Upside55.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering27
BioMarin Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Business StrategyThe newly announced long-term strategy will aim to maximize commercial potential while improving operational efficiency, which should increase value for investors with shares being trading at five-year low.
Financial PerformanceBioMarin's recent valuation is seen as the floor, with expectations of significant revenue growth and margin improvement.
Revenue GrowthThe significant untapped market for Voxzogo should support continued revenue growth, and its broad label allowing for early treatment initiation should help BioMarin to defend market dominance.
Bears Say
Investor ConcernsThe apparent slowing of growth in Voxzogo, which is viewed as a 'make or break' franchise for BioMarin, could disappoint investors.
Market CompetitionThe convenience of TransCon CNP, which is a weekly subcutaneous injection, could be a key competitive advantage as compared to Voxzogo which is a daily subcutaneous injection.
Revenue GrowthVoxzogo sales were generally in line with expectations but were not exceptional due to slower patient growth, adding only 300 patients this quarter compared to 400-500 in previous quarters.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $63.22 and its highest was $99.56 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
Currently, no data Available
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Feb 20, 2025 which is in 95 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Oct 29, 2024. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.531 by $0.019.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is $0.55.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 190,583,020 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $0.55 in its last earnings report, beating expectations of $0.531. Following the earnings report the stock price went down -4.62%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Among the largest hedge funds holding BioMarin Pharmaceutical’s share is PRIMECAP Management Co. It holds BioMarin Pharmaceutical’s shares valued at 1B.
---
BioMarin Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$98.52 (55.35% Upside)
$98.52 (55.35% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 77.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $350.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.15%
12-Months-Change
Fundamentals
Return on Equity
6.25%
Trailing 12-Months
Asset Growth
1.38%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
---
BMRN Company Deck
---
BMRN Earnings Call
Q3 2024
0:00 / 0:00
---
BMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BMRN Stock 12 Month Forecast
Average Price Target
$98.52
▲(55.35% Upside)
Technical Analysis
Best Analysts Covering BMRN
1 Year
1 Year Success Rate
23/47 ratings generated profit
1 Year Average Return
-2.14%
assigned a buy rating 19 days ago
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 48.94% of your transactions generating a profit, with an average return of -2.14% per trade.
---